MeSH Review:
Myelodysplastic Syndromes
Bunjes,
Buchmann,
Duncker,
Seitz,
Kotzerke,
Wiesneth,
Dohr,
Stefanic,
Buck,
Harsdorf,
Glatting,
Grimminger,
Karakas,
Munzert,
Döhner,
Bergmann,
Reske,
Hellström-Lindberg,
Ahlgren,
Beguin,
Carlsson,
Carneskog,
Dahl,
Dybedal,
Grimfors,
Kanter-Lewensohn,
Linder,
Luthman,
Löfvenberg,
Nilsson-Ehle,
Samuelsson,
Tangen,
Winqvist,
Oberg,
Osterborg,
Ost,
Giles,
Stopeck,
Silverman,
Lancet,
Cooper,
Hannah,
Cherrington,
O'Farrell,
Yuen,
Louie,
Hong,
Cortes,
Verstovsek,
Albitar,
O'Brien,
Kantarjian,
Karp,
Matthews,
Appelbaum,
Eary,
Fisher,
Durack,
Hui,
Martin,
Mitchell,
Press,
Storb,
Bernstein,
Harada,
Harada,
Tanaka,
Kimura,
Inaba,
Hermans,
Antonissen,
Ward,
Mayen,
Ploemacher,
Touw,
- Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Tartaglia, M., Niemeyer, C.M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J.D., Gelb, B.D. Nat. Genet. (2003)
- DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis. Inokuchi, K., Miyake, K., Takahashi, H., Dan, K., Nomura, T. J. Clin. Invest. (1996)
- Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate. Pinto, A., Aldinucci, D., Gattei, V., Zagonel, V., Tortora, G., Budillon, A., Cho-Chung, Y.S. Proc. Natl. Acad. Sci. U.S.A. (1992)
- The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Nucifora, G., Begy, C.R., Erickson, P., Drabkin, H.A., Rowley, J.D. Proc. Natl. Acad. Sci. U.S.A. (1993)
- Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Antin, J.H., Smith, B.R., Holmes, W., Rosenthal, D.S. Blood (1988)
- Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Andersson, B.S., Gajewski, J., Donato, M., Giralt, S., Gian, V., Wingard, J., Tarantolo, S., Fernandez, H., Hu, W.W., Blume, K., Kashyap, A., Forman, S.J., Champlin, R.E. Bone Marrow Transplant. (2000)
- The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. Brodeur, G.M. N. Engl. J. Med. (1994)
- Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. Vadhan-Raj, S., Keating, M., LeMaistre, A., Hittelman, W.N., McCredie, K., Trujillo, J.M., Broxmeyer, H.E., Henney, C., Gutterman, J.U. N. Engl. J. Med. (1987)
- Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. Hermans, M.H., Antonissen, C., Ward, A.C., Mayen, A.E., Ploemacher, R.E., Touw, I.P. J. Exp. Med. (1999)
- Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms. Fütterer, A., Campanero, M.R., Leonardo, E., Criado, L.M., Flores, J.M., Hernández, J.M., San Miguel, J.F., Martínez-A, C. J. Clin. Invest. (2005)
- Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Chen, H., Sandler, D.P., Taylor, J.A., Shore, D.L., Liu, E., Bloomfield, C.D., Bell, D.A. Lancet (1996)
- Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly. Worsley, A., Mufti, G.J., Copplestone, J.A., Oscier, D.G., Hamblin, T.J. Lancet (1986)
- Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Clark, R.E., Jacobs, A., Lush, C.J., Smith, S.A. Lancet (1987)
- Treatment of advanced myelodysplastic syndrome with alfacalcidol. Mehta, A.B., Kumaran, T.O., Marsh, G.W., McCarthy, D.M. Lancet (1984)
- Effect of isotretinoin on survival of patients with myelodysplastic syndrome. Tricot, G. Lancet (1987)
- Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Ohno, R., Naoe, T., Hirano, M., Kobayashi, M., Hirai, H., Tubaki, K., Oh, H. Blood (1993)
- Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Kreider, B.L., Orkin, S.H., Ihle, J.N. Proc. Natl. Acad. Sci. U.S.A. (1993)
- The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Parker, J.E., Mufti, G.J., Rasool, F., Mijovic, A., Devereux, S., Pagliuca, A. Blood (2000)
- Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. Backx, B., Broeders, L., Löwenberg, B. Blood (1992)
- Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays. Lee, Y.T., Miller, L.D., Gubin, A.N., Makhlouf, F., Wojda, U., Barrett, A.J., Liu, E.T., Miller, J.L. Blood (2001)
- Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Harada, H., Harada, Y., Tanaka, H., Kimura, A., Inaba, T. Blood (2003)
- The myelodysplastic syndromes: current approaches to therapy. Cheson, B.D. Ann. Intern. Med. (1990)
- Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A., Ost, A. Blood (1998)
- Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Bunjes, D., Buchmann, I., Duncker, C., Seitz, U., Kotzerke, J., Wiesneth, M., Dohr, D., Stefanic, M., Buck, A., Harsdorf, S.V., Glatting, G., Grimminger, W., Karakas, T., Munzert, G., Döhner, H., Bergmann, L., Reske, S.N. Blood (2001)
- Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome. Ayanlar-Batuman, O., Shevitz, J., Traub, U.C., Murphy, S., Sajewski, D. Blood (1987)
- Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Miyagi, T., Ahuja, H., Kubota, T., Kubonishi, I., Koeffler, H.P., Miyoshi, I. Leukemia (1993)
- Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Hoefsloot, L.H., van Amelsvoort, M.P., Broeders, L.C., van der Plas, D.C., van Lom, K., Hoogerbrugge, H., Touw, I.P., Löwenberg, B. Blood (1997)
- SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Giles, F.J., Stopeck, A.T., Silverman, L.R., Lancet, J.E., Cooper, M.A., Hannah, A.L., Cherrington, J.M., O'Farrell, A.M., Yuen, H.A., Louie, S.G., Hong, W., Cortes, J.E., Verstovsek, S., Albitar, M., O'Brien, S.M., Kantarjian, H.M., Karp, J.E. Blood (2003)
- The t(11;20)(p15;q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Ahuja, H.G., Felix, C.A., Aplan, P.D. Blood (1999)
- Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Yamaguchi, H., Baerlocher, G.M., Lansdorp, P.M., Chanock, S.J., Nunez, O., Sloand, E., Young, N.S. Blood (2003)
- The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G., Tefferi, A. Blood (2005)
- Evolutionary conservation of zebrafish linkage group 14 with frequently deleted regions of human chromosome 5 in myeloid malignancies. Liu, T.X., Zhou, Y., Kanki, J.P., Deng, M., Rhodes, J., Yang, H.W., Sheng, X.M., Zon, L.I., Look, A.T. Proc. Natl. Acad. Sci. U.S.A. (2002)
- Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Ratanatharathorn, V., Karanes, C., Uberti, J., Lum, L.G., de Planque, M.M., Schultz, K.R., Cronin, S., Dan, M.E., Mohamed, A., Hussein, M. Blood (1993)
- Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Russell, M., List, A., Greenberg, P., Woodward, S., Glinsmann, B., Parganas, E., Ihle, J., Taetle, R. Blood (1994)
- Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Matthews, D.C., Appelbaum, F.R., Eary, J.F., Fisher, D.R., Durack, L.D., Hui, T.E., Martin, P.J., Mitchell, D., Press, O.W., Storb, R., Bernstein, I.D. Blood (1999)
